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1176-173 Mesenchymal Stromal Cell Transplantation Contributes 
to Collateral Response in Tissue lschemia Through 
Release of Arteriogenic Cytokines 
Tim D. Kinnaird Eugenlo Stabile, Mary Susan Burnett, Matie Shou, Yi Fu Zhou, Richard 
Baffour. Cheol Whan Lee. Shmuel Fuchs. Stephen E. Erxitein. Cardiovascular Research 
institute, Washington. DC 
Background: Mesenchymal stromal cell (MSC’s) transplantation is reported to contribute 
to angiogenesis through cell donation to new vessel formation. However, the humoral 
contribution of MSC’s to collateral response is less well characterized. Methods and 
Results: Murine MSC’s were purified usmg double magnetic bead separation of cultured 
bone marrow. Flow cytometry confirmed absence of CD34, CD45, CD31 and CD1 17 sur- 
face markers. and the presence of SH2 and Sea-1 surface markers. Conditioned media 
(CM) was collected after 72 hours of MSC culture. Using ELISA, we demonstrated 
release of: VEGF (375 pglmg protein in normoxia vs 698 pg/mg protein in 1% hypoxia, 
pcO.Ol), bFGF (2320pgImg vs 3970 pg/mg, p<O.O5), placental growth factor (4lOpg/mg 
vs 434pg/mg. p=NS) and MCP-1 (262 pg/mg vs 109 pglmg, p=NS). lmmunoblottlng of 
MSC protein extracts established the presence of metalloproteinase-9, angiopoetin-1 
and angiopoetin-2. CM enhanced proliferation of endothellal cells by 92% and of smooth 
muscle cells by 74%, and increased tube-formation in a dose dependant manner. 10mgl 
ml of anti-VEGF antibody only partially attenuated these effects (40% reduction in prolif- 
eration, no effect on tube formation). Balb/C mice (n=8) underwent distal femoral artery 
ligation; 24 hours later 5x10’ MSCs were injected into the adductor muscle. Compared to 
controls injected with media alone @=a). foot perfusion in MSC-treated mice increased 
by 63% at day 7 and by 67% at day 10 (p=O.O2). MSC transplantation improved limb 
function (ambulatory score 1.25 vs 0.5, p<O.O5). lessened limb ischemia (Ischemic score 
1.0 vs 2.75, ~~0.05) and reduced the incidence of auto-amputation (13% YS 50%) com- 
pared to controls. Conclusions: Injection of mesenchymal stromal cells into the ischemic 
hindlimb contributes to collateral responses through release of arteriogenic cytokines. 
1176-174 Percutaneous Endocardial Versus Selective Coronary 
Venous Cellular Delivery: Comparisons of Transplant 
Efficiency, Distribution, and Efficacy in Reducing Infarct 
Size and Improving Myocardial Function 
ErikT. Price Fumiaki Ikeno, Ralph C. Fenn, Pauline Chu, Jennifer K. Lyons, Peter J. -* 
Fitzgerald, Alan C. Yeung, Paul G. Yock. Mehrdad Rezaee, Stanford University Medical 
Center, Stanford, CA 
Background: Cellular transplantation is an emerging option for the treatment of ischemic 
cardiomyopathy. Percutaneous endocardial delivery (PED) and percutaneous coronary 
venous delivery (PCVD) offer potential advantages in safety, transplant efficiency, and 
targeted distribution for presewabon of myocardium. 
Methods: A total of 22 swine were studied: 6 PED and 4 PCVD for acute feasibility arm; 
and 4 PED, 4 PCVD, and 4 combined controls for chronic efficacy arm (LAD infarct by 
balloon occlusion). Porcine fibroblasts labeled with iron nano-particles were used for 
transplantation. Between 2-2.5xlO”cells were Injected into the infarct area either by PED 
using a BioCardiaTM hellcal infusion catheter, or by PCVD using a single high-pressure 
(100-200 mmHg) injection through a balloon-tipped catheter in the anterior interventricu- 
lar vein (AIV). Ejection fraction (EF) was measured at infarct induction (day 0), cell deliv- 
ery (day 7), and sacrifice (day 28). HorIzontat cross-sections of the left ventricle were 
stained with tetrazollum for infarct size, then with H&E and Prussian Blue for cell Identifi- 
cation. A linear computational model was used to estimate transplant efficiency. 
Results: Acute studies demonstrated safe, targeted transplantation using both modak- 
ties. In infarcted animals, PED and PCVD resulted in 17.3 + 24.3% and 15.7 f 11.6% of 
fibroblasts identified after 21 days. PED resulted in 98.4% of cells in the anteroseptal 
walls, with 95.8% localized to the endocardlal half, at an average depth of 3.4 + 3.9 mm. 
PCVD resulted in 97.6% of cells in the anteroseptal walls, a radial 21.8 f 7.9 mm from 
the AIV, with 60.1% localized to the endocardial half. With both modalities >96.0% of 
cells were within 5 mm of the Infarct zone. Both PED and PCVD trended in reduced inf- 
arct size compared to the controls (3.9 * 1.6 and 7.9 * 6.0, vs. 13.9 f 10.8, ~~0.12 and 
p=O.37 respectively), and improved EF (26.0 * 3.2 and 26.8 * 12.6 vs. 17.0 f 9.8, ~~0.13 
and p=O.27 respectively). 
Conclusions PED and PCVD provide comparable efficiency and targeted distribution. 
As anticipated, PCVD provides regional delivery, and PED a nwre local distribution. 
Studies are underway to further establish the efficacy of both modalities. 
1176-l 75 Catheter-Based Percutaneous Cellular 
Cardiomyoplasty Using Allogeneic Bone Marrow 
Derived Mesenchymal Stem Cells 
Marcus E. St. John Jinsheng Xie, Alan W. Heldman, Garrick C. Stewart, Stephen M. 
Cattaneo, David J. Caparrelli, William A. Baumgartner, Bradley J. Martin, Joshua M. 
Hare, Johns Hopkins Medical Institutions, Baltimore, MD, Osiris Therapeutics, Inc, 
Baltimore, MD 
Backgrounct Bone marrow derived mesenchymal stem cells (MSCs) administered by 
direct injection into a myocardial infarct (Ml) improve ventricular remodeling and global 
function in both large and small animal models. In order to demonstrate therapeutic appli- 
cability without need for surgery. we tested the hypothesis that MSCs delivered percuta- 
neously via catheter successfully engraft, migrate throughout a region of MI. and 
demonstrate evidence of myocyte differentiatmn in pigs. Methods: MI was produced by 
l-hour occlusion of the left anterior descending artery in domestic swne (weight 30. 
45kg). Three days later either 200 million Dil and DAPI-labeled allogeneic porcine MSCs 
or vehicle alone (randomly assigned; total n=9) were injected into the LV (lo-12 sites in 
the endocardium within the infarct zone) via a helical needle infusion catheter advanced 
through a deflectable guide catheter (BioCardia, Inc, CA). Results: Animals were eutha- 
nized between 2 to 8 weeks after injection. Pathology revealed transmural anteroseptal 
infarcts. MSC engraftment was observed in all treated animals, with transmural migration 
of implanted cells from endocardium to epicardium. MSCs were found associated with 
blood vessel walls and co-stained for factor VIII, consistent with neoangiogenesls. Trans- 
planted MSCs expressed muscle specific proteins including phospholamban, myosin 
heavy chain and alpha-actinin, which were not present before implantation, suggesting 
myogenic differentiation. Implanted MSCs were not found in regions of myocardium 
remote from the injection site, or systemically. There was no evidence of immunorejec- 
tion. No deaths, perforations or arrhythmias resulted from the catheterization or In@- 
tions. Conclusions MSCs can be successfully delivered via percutaneous catheter. 
Transplanted cells engraft, migrate transmurally, express myocyte phenotypic markers 
and may participate in neoangenesis. We conclude that catheter-based delivery of allo- 
geneic MSCs is both safe and effective and will facilitate practical application of stem cell 
technology !n the treatment of Ml and potentially other cardlomyopathic processes. 
1176-176 Safety of Autologous Bone Marrow Cell Injection in 
Humans With Severe lschemic Heart Failure 
Hans F. Dohmann. Emerson C. Perin, Andre Luiz S. Sousa, Radovan Borojevic, Antonio 
C. Catvalho, Isabel Rossi, Suzana A. Silva, Robeno Esporcatte. Guilherme V. Silva, 
Hans J. Dohmann, Fernando Rangel, James T. WilIerson. Texas Heart Institute, 
Houston, TX, Hospital Procardiaco, RIO de Janeiro, Brazil 
Background Severe ischemic heart failure (HF) in patients not amenable to revascular- 
ization carries a high mortakty. Treatment of this high risk gorup witn injection of myo- 
blasts revealed a high incidence of post-procedural malignant ventricular arrhythmcas. 
We evaluated the safety of transendocardial (TE) injections of bone marrow mononu- 
clear cells (BMNC) to treat pts with severe HF. Methods Fourteen pts (60 * 10 yrs, 12 
males) with refractory symptoms (CCSINYHA Ill-IV), LV dysfunction (EF 19 * 10 %) 
were included in the study. Bone marrow (5Oml) was aspirated and EMNCs were iso- 
lated. TE injections (15*2 sites, 0.2~~) were performed using the Myo-Star catheter 
(NOGA, B~osense). Pts were evaluated for post-procedural in-hospital events and 24h- 
Halter was peltormed as well as serial echocardiograms, cardiac enzymes and C- reac- 
tive protein (CRP) at baseline, 6h. 12h, 24h and 48 hours. Eight wks follow-up included 
24h-Holler and CRP levels. Student’s T-test was used for comparison. 
Results No in-hospital major events were observed. Minor events Included transient 
hypotension with pulmonary congestion (n=l) and frequent PVCs (n=l) on day 1. CK-MB 
did not increase (peak 3.0tl.5 mcg/l, normal ~5 mcg/l) and Troponin I was mildly ele- 
vated (peak 1.0+0.7 nglml, normal < 0.4 nglml).CRP levels increased from 0.955 0.68 to 
2.0 t 0.70 mg/dl (p=O.O03) at 24h and decreased at 8 weeks (1.27+1 1 mg/dl; p=O.4). No 
pericardial effusions were detected by echo. No malignant or sustained ventricular 
arrhythmias were detected post procedure and all pts were discharged after 48h. PVC’s 
at 24h post-procedure were similar to baseline 49.2 x103 vs 29x103 (~~0.12). respec- 
tively.At 8 wks there was a trend to a decrease in PVC’s from baseline 10.3~10~ 
(p=O.OB). Late events included one uncomplicated NSTMI at 7 days. No deaths occured. 
Conclusiolr Immediate and short-term follow-up of pts recieveing BMNC injections 
revealed mild elevations in CRP and troponin I at 24 hours and one cardiac event. No 
malignant arrhythmias were detected post procedure and in follow-up. BMNC therapy in 
these high risk pts was safe in follow-up to 8 weeks. 
1176-177 The Coronary Sinus: A Safe and Effective Route for 
Percutaneous Myoblast Transplantation 
Camille Brass&t, Claire Carrion, Patrick Bruneval, Didier Heudes, Ketty Schwartz, 
Albert Hagi?ge, Jean-Thomas Vilquin. Emmanuel Messas, Michel Desnos, Antoine 
Lafont, Philippe Menasch(?, Hopital Europ&?n Georges Pompidou, Paris, France, lnstitut 
de Myologie, Paris, France 
The potential of autologous skeletal myoblast (SM) transplantation to improve function of 
Infracted myocardium has been previously documented using epicardial injections. In 
search for alternate, less invasive approach, we assessed the safety and feasibility of 
percutaneous SM transfer through the coronary sinus system. Two pigs and 4 sheep 
underwent transfemoral cathetetisation of the anterior interventricular vein using a dedi- 
cated catheter (TransAccess@, Transvascular, Menlo Park, CA) which incorporates a 
tipped-phase-array ultrasound probe for guidance and an extendable needle for myocar- 
dial access. Upon correct positioning, the needle was pulled forward to the puncture the 
venous wall and a mIcroInfusion catheter was advanced through it to inject the cell sus- 
pension. Cultured SM (2x108) were thus intramyocardially delivered in 4 staged sites 
along the catheter tract. Two hours later, the hearts were explanted and processed for 
